Show Notes
ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The BioCentury Show, Genge discusses progress in pathway prioritization, progression-rate prediction, and endpoint standardization with BioCentury's Selina Koch. On the biology side, Genge expects the field to converge on a small number of high-priority pathways. SOD1 is the firs...
More from The BioCentury Show
Tigermed, the largest clinical CRO in China, has expanded into more than 50 countries and is growing its North American operations, offering full-service support from preclinical through Phase IV. On this sponsored edition of The BioCentury Show, Britney Winterberger, Tigermed’s VP and head of North America clinical operations, tells BioCentury Executive Editor Jeff Cranmer how the CRO helps U.S. sponsors run trials in China and Chinese sponsors run trials in the U.S. — and why combining both...
Arrowhead Pharmaceuticals can now deliver siRNA to seven cell types, and new data showing subcutaneous delivery to the brain could push RNAi therapies well beyond the liver. On this edition of The BioCentury Show, Arrowhead Chairman, President, and CEO Chris Anzalone joins BioCentury’s Stephen Hansen to discuss where siRNA has the edge over ASOs, what the Phase III miss for Novartis’ pelacarsen means for olpasiran, the Lp(a) therapy Arrowhead partnered with Amgen, and the growth outlook for p...
Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant, co-founder and first CEO of Day One, which Servier acquired for $2.5 billion this year. In an interview with BioCentury's Lindsay Martin, Grant discussed white spaces in women's health such as migraine and anemia, and why mid-tier acquirers like Jazz, Ipsen and Servier make smaller markets viable. She also explained why the l...
On this edition of The BioCentury Show, Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to Blackstone's new $6.3 billion fund, and the goal of game-changing bets. Galakatos discusses Blackstone's thesis for addressing the late-stage financing gap, as Phase III programs costing more than $1 billion drive demand for large, product-based capital. He also addresses structured capital as an alternative to acquisition...
On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to discuss genetics as a scalable drug discovery platform and the practical use of AI in genomics. View full story: https://www.biocentury.com/article/660697 #Genomics #DrugDiscovery #AI #GeneticMedicines #ClinicalTrials 0:00 - Introduction 1:14 - Regeneron Genetics Center 10:29 - Acting on Genetic Signals 16:57 ...